Completed PHASE3 INTERVENTIONAL NCT00252824

STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma

A Comparison of the Efficacy of Symbicort® Single Inhaler Therapy (Symbicort Turbuhaler® 160/4.5 mg 1 Inhalation b.i.d. Plus As-needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults - a 26 Weeks, Randomised, Open-label, Parallel-group, Multicentre Study

Sponsor: AstraZeneca

Conditions Asthma

Interventions Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy

Updated 6 times since 2017 Last updated: Jan 21, 2011 Started: Jul 31, 2005 Completion: Dec 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00252824, this PHASE3 trial focuses on Asthma and remains completed. Sponsored by AstraZeneca, it has been updated 6 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ahens, Greece , Akureyri, Iceland , Alexandroup, Greece , Athens, Greece , Aveiro, Portugal , Banská Bystrica, Slovakia , Bardejov, Slovakia , Bratislava, Slovakia , Brno, Czechia , Celje, Slovenia and 43 more locations